Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, rheumatoid arthritis and Crohn's disease, but its use for GCA is still pending ...

Genmab categorically refutes these allegations and will vigorously defend the company against AbbVie’s claims. Genmab notes that this is yet another lawsuit among multiple recent lawsuits filed by ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie has not pursued any development of products incorporating their alleged trade secrets. Genmab categorically refutes these allegations and will vigorously defend the company against AbbVie ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously ...

AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research company, Gubra. While the ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...